Dec 10, 2021 / 02:30PM GMT
Operator
Good morning, everyone, and welcome to today's call, where we will review data updates from MARIO-3 from patients with PD-L1 positive and PD-L1 negative tumors in frontline metastatic triple-negative breast cancer. Participants on today's call are: Adelene Perkins, Chief Executive Officer; Dr. Robert Ilaria, Chief Medical Officer from Infinity Pharmaceuticals; and Dr. Hatem Soliman, Director of the Clinical Trials Unit at Moffitt Cancer Center.
During this call, we may make forward-looking statements about our future expectations and plans, including the clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and financial projections. Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the Risk Factors section of our annual and quarterly reports and in other filings we make with the SEC. These forward-looking statements represent our views only as of today. And we caution you that we may not update them in the future, whether as a result of new
Infinity Pharmaceuticals Inc at 2021 San Antonio Breast Cancer Symposium - Conference Call Transcript
Dec 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers